ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): The Annual General Meeting of ALK-Abelló A/S will be held on Thursday 18 March 2021 at 4.00pm (CET) as a fully electronic Annual General Meeting. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.
Shareholders who have registered their attendance can participate in the Annual General Meeting via VP’s VGM portal. The Annual General Meeting will also be webcast live at ALK’s website: https://ir.alk.net/agm.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Digitalist Group Oyj6.11.2025 15:46:37 CET | Press release
Digitalist Group Oy - Managers' Transactions
Bavarian Nordic A/S6.11.2025 15:03:23 CET | Press release
Consortium consisting of Nordic Capital and Permira announces preliminary result of the takeover offer to shareholders of Bavarian Nordic and that the Offer is withdrawn and will not be completed
Bavarian Nordic A/S6.11.2025 15:03:23 CET | Pressemeddelelse
Konsortium bestående af Nordic Capital og Permira offentliggør det foreløbige resultat af overtagelsestilbuddet til aktionærerne i Bavarian Nordic og at Tilbuddet tilbagekaldes og ikke vil blive gennemført
Investeringsforeningen Wealth Invest6.11.2025 15:02:04 CET | Press release
Meddelelse om fejl NAV i Wealth Invest AlphaCura
Alvotech6.11.2025 15:00:00 CET | Press release
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom